SI2152663T1 - Tri-arilne spojine in sestavki, ki vsebujejo isto - Google Patents

Tri-arilne spojine in sestavki, ki vsebujejo isto

Info

Publication number
SI2152663T1
SI2152663T1 SI200831209T SI200831209T SI2152663T1 SI 2152663 T1 SI2152663 T1 SI 2152663T1 SI 200831209 T SI200831209 T SI 200831209T SI 200831209 T SI200831209 T SI 200831209T SI 2152663 T1 SI2152663 T1 SI 2152663T1
Authority
SI
Slovenia
Prior art keywords
tri
compositions
same
aryl compounds
aryl
Prior art date
Application number
SI200831209T
Other languages
English (en)
Inventor
Esther Priel
Aviv Gazit
Shimon Slavin
Sara Yitzchak
Original Assignee
Ben Gurion University Of The Negev Research And Development Authority
Shimon Slavin
Aviv Gazit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University Of The Negev Research And Development Authority, Shimon Slavin, Aviv Gazit filed Critical Ben Gurion University Of The Negev Research And Development Authority
Publication of SI2152663T1 publication Critical patent/SI2152663T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
SI200831209T 2007-06-04 2008-06-03 Tri-arilne spojine in sestavki, ki vsebujejo isto SI2152663T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92487507P 2007-06-04 2007-06-04
US92952407P 2007-07-02 2007-07-02
US92952507P 2007-07-02 2007-07-02
US692408P 2008-02-06 2008-02-06
PCT/IL2008/000747 WO2008149345A2 (en) 2007-06-04 2008-06-03 Tri-aryl compounds and compositions comprising the same
EP08763505.8A EP2152663B1 (en) 2007-06-04 2008-06-03 Tri-aryl compounds and compositions comprising the same

Publications (1)

Publication Number Publication Date
SI2152663T1 true SI2152663T1 (sl) 2014-08-29

Family

ID=40094272

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831209T SI2152663T1 (sl) 2007-06-04 2008-06-03 Tri-arilne spojine in sestavki, ki vsebujejo isto
SI200831358T SI2152256T1 (sl) 2007-06-04 2008-06-04 Aktivirne spojine telomeraze in postopki za njihovo uporabo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831358T SI2152256T1 (sl) 2007-06-04 2008-06-04 Aktivirne spojine telomeraze in postopki za njihovo uporabo

Country Status (19)

Country Link
US (7) US8604245B2 (sl)
EP (3) EP2152663B1 (sl)
JP (6) JP5508258B2 (sl)
KR (4) KR101560844B1 (sl)
CN (4) CN101742906A (sl)
AU (2) AU2008259342B2 (sl)
CA (4) CA2690004C (sl)
CY (1) CY1115919T1 (sl)
DK (2) DK2152663T3 (sl)
EA (4) EA021544B1 (sl)
ES (2) ES2465216T3 (sl)
HR (2) HRP20140394T1 (sl)
IL (4) IL202425A (sl)
MX (2) MX2009013354A (sl)
PL (2) PL2152663T3 (sl)
PT (2) PT2152663E (sl)
SI (2) SI2152663T1 (sl)
TW (1) TWI430796B (sl)
WO (3) WO2008149346A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021544B1 (ru) * 2007-06-04 2015-07-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Триарильные соединения и фармацевтические композиции, их содержащие
AU2009331298B2 (en) * 2008-12-22 2015-04-30 Pola Chemical Industries Inc. Melanin production inhibitor
EP2437606B1 (en) 2009-05-18 2016-07-27 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
JP6657101B2 (ja) * 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
IL257470B2 (en) * 2018-02-11 2023-12-01 Ben Gurion Univ Of The Negev Research And Development Authority Telomerase activator compounds for use in fertility and related applications
AU2018218003B2 (en) 2017-02-12 2024-02-08 Neuromagen Pharma Ltd. Telomerase activating compounds for use in fertility and related applications
KR102099335B1 (ko) 2017-11-03 2020-04-09 한국과학기술연구원 Prox1의 발현 또는 활성 조절제를 포함하는 텔로머라제 역전사효소의 발현 조절용 조성물 또는 텔로머라제 역전사효소 조절제의 스크리닝 방법
US10098922B1 (en) * 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
TW202024006A (zh) * 2018-08-24 2020-07-01 日商三菱瓦斯化學股份有限公司 化合物，及包含其之組成物，以及阻劑圖型之形成方法及絕緣膜之形成方法
WO2020141525A1 (en) * 2018-12-31 2020-07-09 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Capture flow assay device and methods
KR102214612B1 (ko) 2020-03-23 2021-02-15 한국과학기술연구원 Prox1의 발현 또는 활성 조절제를 포함하는 텔로머라제 역전사효소의 발현 조절용 조성물 또는 텔로머라제 역전사효소 조절제의 스크리닝 방법
KR102647261B1 (ko) 2023-05-04 2024-03-14 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102647264B1 (ko) 2023-11-01 2024-03-14 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093557A (en) * 1976-09-16 1978-06-06 Hercules Incorporated Process for inhibiting corrosion of metals in aqueous systems
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4740330A (en) * 1986-09-03 1988-04-26 The Dow Chemical Company Method for allylating aromatic hydroxyl-containing compounds
US4835202A (en) * 1987-11-20 1989-05-30 Ciba-Geigy Corporation (Hydroxyphenyl) phosphine stabilized compositions
US4783495A (en) * 1987-11-20 1988-11-08 Ciba-Geigy Corporation (Hydroxyphenyl) silane stabilizers
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
JPH02121941A (ja) * 1988-10-28 1990-05-09 Teijin Chem Ltd ハロゲン化トリスフェニル誘導体および難燃性熱可塑性樹脂組成物
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5219727A (en) * 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04268328A (ja) * 1991-02-22 1992-09-24 Idemitsu Petrochem Co Ltd 分岐ポリカーボネート
JPH04328555A (ja) * 1991-04-26 1992-11-17 Fuji Photo Film Co Ltd ポジ型フオトレジスト組成物
US5198531A (en) * 1991-06-14 1993-03-30 Research Diagnostic Antibodies Polymeric resin for peptide synthesis
WO1993015063A1 (en) 1992-02-03 1993-08-05 Hoechst Celanese Corporation Uv light stabilizing, antioxidant and colorant compounds
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP3534787B2 (ja) * 1993-05-06 2004-06-07 本州化学工業株式会社 トリスフェノールへのヒドロキシベンジル基付加体
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
JP3026707B2 (ja) * 1993-10-05 2000-03-27 出光石油化学株式会社 分岐状ポリカーボネートの製造方法
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
WO1996008240A1 (en) * 1994-09-16 1996-03-21 President And Fellows Of Harvard College Use of aromatic halides for treating mammalian cell proliferation
US6028103A (en) * 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
DE4439947A1 (de) 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
NZ332103A (en) * 1996-03-20 2000-08-25 Nuchem Pharmaceuticals Inc Triphenyl methane compounds or analogues thereof where one or more of the phenyl groups is substituted and the tertiary carbon atom is replaced for sickle cell disease,
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
JP4128247B2 (ja) * 1996-11-01 2008-07-30 株式会社リコー フェノール系化合物及び電子写真感光体
JPH10153884A (ja) * 1996-11-25 1998-06-09 Minolta Co Ltd 静電潜像現像用トナー
EP0981611A1 (en) 1997-02-05 2000-03-01 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
DE19711617A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
WO2000001495A1 (en) 1998-07-02 2000-01-13 Millipore Corporation Process for coating a solid surface with a liquid composition
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
DE19844547C2 (de) 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6380378B1 (en) * 1998-12-24 2002-04-30 Toagosei Company, Ltd. Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6417208B1 (en) 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
JP4195145B2 (ja) * 1999-04-01 2008-12-10 出光興産株式会社 ポリカーボネートの製造方法
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE60043346D1 (de) * 1999-07-28 2009-12-31 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU7961800A (en) * 1999-10-28 2001-05-08 Kyowa Hakko Kogyo Co. Ltd. Thiazolidinedione derivatives
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
KR100875335B1 (ko) 1999-12-22 2008-12-22 메타베이시스 테라퓨틱스, 인크. 신규 비스아미데이트 포스포네이트 프로드러그
US6803375B1 (en) * 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
JP4187934B2 (ja) * 2000-02-18 2008-11-26 富士フイルム株式会社 ポジ型レジスト組成物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1307183A2 (en) 2000-08-11 2003-05-07 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
EP1330456B8 (en) * 2000-10-12 2012-02-08 Cancer Research Technology Limited N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040132830A1 (en) * 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
CA2436576A1 (en) 2001-02-02 2002-08-08 Pfizer Inc. Treatment of diabetes mellitus using vardenafil
SK14912003A3 (sk) 2001-06-07 2004-09-08 Eli Lilly And Company Modulátory receptorov aktivovaných peroxizomálnymi proliferátormi (PPAR)
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7045523B2 (en) * 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003066814A2 (en) * 2002-02-04 2003-08-14 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
BR0308415A (pt) 2002-03-14 2005-02-15 Bayer Pharmaceuticals Corp Métodos de tratamento de diabetes usando-se inibidores de pde11a
MXPA05009242A (es) 2003-03-17 2006-04-18 Pfizer Prod Inc Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP4517723B2 (ja) * 2003-05-22 2010-08-04 住友ベークライト株式会社 ナフトキノンジアジドスルホン酸エステル、それを用いたポジ型感光性樹脂組成物、半導体装置及び表示素子
NZ544191A (en) * 2003-06-23 2008-12-24 Geron Corp Compositions and methods for increasing telomerase activity
EA012110B1 (ru) 2003-06-30 2009-08-28 Алтана Фарма Аг Пирролодигидроизохинолины как ингибиторы pde10
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
US20050049208A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
EP1737984A4 (en) * 2004-04-07 2009-11-04 Qiagen North American Holdings ONE COMPONENT AND TWO-COMPONENT DNA POL III REPLICAS AND THEIR USE
US20090162286A1 (en) 2004-06-07 2009-06-25 Pfizer Inc. Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
JP4929569B2 (ja) * 2004-08-20 2012-05-09 東レ株式会社 高分子電解質材、ならびにそれを用いた高分子電解質膜、膜電極複合体および高分子電解質型燃料電池
US7541392B2 (en) * 2004-09-14 2009-06-02 E.I. Du Pont De Nemours And Company Materials leading to improved dental composites and dental composites made therefrom
JP2008528634A (ja) * 2005-01-31 2008-07-31 セプション・セラピューティクス・インコーポレーテッド 腫瘍壊死因子インヒビター
CA2594505A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
JP5211438B2 (ja) * 2005-06-09 2013-06-12 東レ株式会社 樹脂組成物およびそれを用いた表示装置
EP2066680B1 (en) * 2006-09-28 2012-08-08 Medical Research Council Triphenylphosphonium thionitrite nitric oxide donors
EA021544B1 (ru) * 2007-06-04 2015-07-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Триарильные соединения и фармацевтические композиции, их содержащие

Also Published As

Publication number Publication date
EP2826472A3 (en) 2015-05-20
HRP20141264T1 (hr) 2015-05-08
KR20100039830A (ko) 2010-04-16
CN104000806B (zh) 2017-09-15
CN101742994A (zh) 2010-06-16
AU2008259342B2 (en) 2014-07-10
MX2009013354A (es) 2010-07-06
JP2010529961A (ja) 2010-09-02
PL2152256T3 (pl) 2015-03-31
WO2008149353A2 (en) 2008-12-11
CA2963857A1 (en) 2008-12-11
JP6134824B2 (ja) 2017-05-24
CA2690013A1 (en) 2008-12-11
CA2690013C (en) 2016-02-09
DK2152663T3 (da) 2014-06-23
WO2008149345A2 (en) 2008-12-11
US20140107336A1 (en) 2014-04-17
ES2527759T3 (es) 2015-01-29
AU2008259342A1 (en) 2008-12-11
EA022472B1 (ru) 2016-01-29
SI2152256T1 (sl) 2015-04-30
KR101560844B1 (ko) 2015-10-15
US20100256382A1 (en) 2010-10-07
KR101600374B1 (ko) 2016-03-07
JP2016145199A (ja) 2016-08-12
JP2010529107A (ja) 2010-08-26
US20100267667A1 (en) 2010-10-21
WO2008149353A3 (en) 2010-02-25
EP2152256A4 (en) 2011-11-02
TWI430796B (zh) 2014-03-21
KR20160051682A (ko) 2016-05-11
IL240895A0 (en) 2015-10-29
CY1115919T1 (el) 2017-01-25
EP2152663A4 (en) 2011-11-09
PL2152663T3 (pl) 2014-09-30
PT2152256E (pt) 2015-02-04
CN101742906A (zh) 2010-06-16
US10214481B2 (en) 2019-02-26
JP2015007068A (ja) 2015-01-15
WO2008149346A2 (en) 2008-12-11
MX2009013353A (es) 2010-07-06
WO2008149346A3 (en) 2010-02-25
JP2017019774A (ja) 2017-01-26
HRP20140394T1 (hr) 2014-08-01
EP2152256A2 (en) 2010-02-17
US20140142067A1 (en) 2014-05-22
US20170305837A1 (en) 2017-10-26
US20140142068A1 (en) 2014-05-22
EA201500403A1 (ru) 2016-01-29
JP5922328B2 (ja) 2016-05-24
PT2152663E (pt) 2014-06-03
JP5508258B2 (ja) 2014-05-28
AU2008259350B2 (en) 2013-06-06
CN101742994B (zh) 2014-06-11
KR20170029015A (ko) 2017-03-14
CN103553939A (zh) 2014-02-05
IL202424A (en) 2017-01-31
US8609736B2 (en) 2013-12-17
IL202425A (en) 2015-09-24
JP5964898B2 (ja) 2016-08-03
US20170305836A1 (en) 2017-10-26
CA2690004A1 (en) 2008-12-11
IL202425A0 (en) 2010-06-30
WO2008149345A3 (en) 2010-02-25
US9663448B2 (en) 2017-05-30
CA2913459A1 (en) 2008-12-11
CA2690004C (en) 2018-01-23
DK2152256T3 (en) 2015-01-19
US9670139B2 (en) 2017-06-06
EA021544B1 (ru) 2015-07-30
EA201401193A1 (ru) 2015-08-31
EA200971140A1 (ru) 2010-10-29
JP2017149762A (ja) 2017-08-31
TW200916101A (en) 2009-04-16
EP2826472A2 (en) 2015-01-21
US9670138B2 (en) 2017-06-06
EP2152256B1 (en) 2014-10-15
AU2008259350A1 (en) 2008-12-11
KR20100039828A (ko) 2010-04-16
CN104000806A (zh) 2014-08-27
US8604245B2 (en) 2013-12-10
IL249838A0 (en) 2017-02-28
CN103553939B (zh) 2018-02-02
ES2465216T3 (es) 2014-06-05
EP2152663B1 (en) 2014-03-19
IL202424A0 (en) 2010-06-30
EA200971141A1 (ru) 2010-10-29
EP2152663A2 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
IL240895A0 (en) Tri-aryl compounds and preparations containing them
IL242374A (en) Baryl compounds and their pharmaceutical preparations
EP2130843A4 (en) POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS
PT2114900T (pt) Compostos à base de tiopirimidina e as suas utilizações
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
IL199656A0 (en) Tablet-in-tablet compositions
HK1168843A1 (zh) 取代的喹喔啉型呱啶化合物及其用途
HUE059171T2 (hu) Kompozíciók
GB0724342D0 (en) Anitbacterial compositions
ZA201001300B (en) Antigen-asjuvant compositions and methods
GB0711683D0 (en) Compositions
GB0700534D0 (en) Composition
GB0712024D0 (en) Compositions
IL210226A (en) Azul compound and pharmaceutical preparations containing them
GB0721291D0 (en) Methods and compositions
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof
GB0719526D0 (en) Compositions and methods
EP2247303A4 (en) HEMOSTASE MODULATING COMPOSITIONS AND USES THEREFOR
GB0715428D0 (en) Compositions and uses thereof
EP2170874A4 (en) NEW COMPOUNDS AND THEIR USE
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
EP2214697A4 (en) COMPOSITIONS OF NELL-1
GB0708445D0 (en) Compounds and uses thereof